Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older
- People whose overall health and ability to carry out daily activities meets a specific standard, rated 0 or 1 on a scale used by doctors called the ECOG Performance Status (confirm with trial site)
- People with a life expectancy of at least 12 weeks
- People who have cancer that can be measured on a scan, according to a standard set of guidelines called RECIST v1.1
- People whose organs (such as kidneys and liver) and bone marrow are functioning well enough to meet the trial's requirements
- People who have a confirmed change or mutation in a gene called EGFR, as shown in their medical records
Who may not be able to join:
- People who currently have an active infection, including tuberculosis, hepatitis B (HBV), hepatitis C (HCV), or HIV
- People who have cancer that has spread to the brain and is currently active or has not yet been treated
- People who have cancer that has spread to the membranes surrounding the brain or spinal cord, or who have pressure on their spinal cord
- People who have serious heart or blood vessel conditions (confirm with trial site for specific definitions)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 8610 84148921
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Adverse Events (AEs); Incidence of Serious Adverse Events (SAEs); Incidence of dose-limiting toxicities (DLT) as defined in the protocol; Incidence of baseline laboratory finding, ECG and vital signs changes
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.